China

Haiwen & Partners is one of the earliest domestic law firms in China to engage in foreign and overseas dispute resolution and arbitration. The dispute resolution team consists of more than ten partners and counsels, and over forty professional lawyers. Based in the firm’s office in Beijing, partner Chao Yang has nearly 20 years of experience in dispute resolution, focusing on commercial arbitration and litigation. She specialises in disputes involving investment and financing, capital management, corporate matters, international trade, and Sino-foreign joint ventures.  

In a landmark pharmaceutical patent invalidation, the firm acted for Qilu Pharmaceutical in successfully challenging Eisai R&D Management Co's lenvatinib polymorph patent across successive proceedings before CNIPA, the Beijing Intellectual Property Court, and the Supreme People's Court, which issued a final judgment affirming non-inventiveness and wiping out the last surviving claim; the firm coordinated the invalidation proceedings with parallel infringement litigation to protect Qilu's generic approval timeline, with the Supreme People's Court's ruling establishing precedential guidance on pharmaceutical crystal-form patents and delivering significant commercial impact by clearing Qilu's path to generic lenvatinib market entry and reducing treatment costs for Chinese patients. 

Client feedback 

"In-depth knowledge of their field of expertise, prompt feedback, professional manners, outstanding project management and excellent communications. No surprises in all the controllable aspects.” – Commercial and transactions 

Huijuan Sun 

“Prompt feedback with professional manners in handling sometimes complex issue. We feel that she is a lawyer we can always trust.”